Addex Therapeutics Ltd
ADXN
$5.89
-$0.01-0.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -82.35% | -40.19% | -- | -- |
| Total Other Revenue | -87.85% | -- | 376.92% | -- | 4,837.50% |
| Total Revenue | -87.85% | 1,064.71% | -8.15% | -65.41% | -70.60% |
| Cost of Revenue | -73.96% | -11.16% | 20.73% | -24.25% | -38.09% |
| Gross Profit | 62.37% | 36.31% | -32.19% | 3.11% | -708.55% |
| SG&A Expenses | -2.57% | 113.73% | 17.53% | -13.19% | -34.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.01% | 95.44% | 18.49% | -16.88% | -35.61% |
| Operating Income | 10.96% | -92.23% | -20.98% | 10.66% | 25.18% |
| Income Before Tax | -30.76% | -69.39% | -11.64% | -47.41% | -94.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.76% | -69.39% | -11.64% | -47.41% | -94.86% |
| Earnings from Discontinued Operations | -- | 76.24% | -- | -99.10% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.76% | -67.47% | -11.46% | -115.67% | 53.60% |
| EBIT | 10.96% | -92.23% | -20.98% | 10.66% | 25.18% |
| EBITDA | 10.65% | -103.06% | -32.35% | -1.80% | 25.17% |
| EPS Basic | -8.38% | -39.29% | 2.78% | -115.32% | 53.87% |
| Normalized Basic EPS | -8.65% | -41.86% | 2.68% | -45.10% | -92.59% |
| EPS Diluted | -8.38% | -39.29% | 2.78% | -115.32% | 53.87% |
| Normalized Diluted EPS | -8.65% | -41.86% | 2.68% | -45.10% | -92.59% |
| Average Basic Shares Outstanding | 20.52% | 19.88% | 14.62% | 2.26% | 0.83% |
| Average Diluted Shares Outstanding | 20.52% | 19.88% | 14.62% | 2.26% | 0.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |